Gary H. Lyman

Gary H. Lyman

Corporate Officer/Principal bij Duke Comprehensive Cancer Center

78 jaar
Consumer Services
Commercial Services
Health Technology

Profiel

Gary H.
Lyman
is currently the Director of Comparative Effectiveness at Duke Comprehensive Cancer Center and a Professor at the University of Washington.
He previously held positions as a Professor and Director of Health Services at the University of Rochester, Co-Director at Fred Hutchinson Cancer Research Center, Professor and Director of Cancer Center at Albany Medical College, Professor at Duke University, the University of South Florida, H.
Lee Moffitt Cancer Center & Research Institute, Inc., USF Health Morsani College of Medicine, and Duke Cancer Institute.
He also served as an Independent Director at Generex Biotechnology Corp.
from 2017 to 2019.
Lyman received his undergraduate and doctorate degrees from the State University of New York at Buffalo.

Actieve functies van Gary H. Lyman

BedrijvenFunctieBegin
Corporate Officer/Principal -
Corporate Officer/Principal -
Alle actieve functies van Gary H. Lyman

Eerdere bekende functies van Gary H. Lyman

BedrijvenFunctieEinde
GENEREX BIOTECHNOLOGY CORPORATION Directeur/Bestuurslid 21-02-2019
Corporate Officer/Principal -
Rochester Christian University Corporate Officer/Principal -
Albany Medical College Corporate Officer/Principal -
University of South Florida Corporate Officer/Principal -
Ervaring van Gary H. Lyman in detail bekijken

Opleiding van Gary H. Lyman

State University of New York at Buffalo Doctorate Degree

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Ervaring van Gary H. Lyman in detail bekijken

Connecties

100 +

Eerstegraads connecties

12

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Persoonlijk netwerk weergeven

Verwante bedrijven

Bedrijven in privébezit5

Health Technology

Commercial Services

Commercial Services

Health Services

Zie bedrijfsconnecties
  1. Beurs
  2. Insiders
  3. Gary H. Lyman
-40 % Aanbod van beperkte duur: onze abonnementen leiden je naar de beste beleggingen van morgen.
PROFITEER NU